RFP
NBIX icon

Root Financial Partners’s Neurocrine Biosciences NBIX Stock Holding History

Root Financial Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$249K Buy
1,477
+323
+28% +$47.9K 0.01% 329
2026
Q1 		$152K Buy
1,154
+955
+480% +$127K 0.01% 412
2025
Q4 		$28.2K Buy
199
+26
+15% +$3.77K ﹤0.01% 983
2025
Q3 		$24.3K Buy
+173
New +$23.4K ﹤0.01% 1017

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Root Financial Partners's NBIX Position: Q2 2026 in Review

Root Financial Partners increased its Neurocrine Biosciences (NBIX) stake by 28% in Q2 2026, buying an estimated $47.9K and bringing the position to 1,477 shares worth $249K. The position accounts for 0.01% of the portfolio, ranked #329.

Root Financial Partners first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Root Financial Partners held 1,477 shares of Neurocrine Biosciences worth $249K as of Q2 2026.
  • Root Financial Partners bought 323 Neurocrine Biosciences shares in Q2 2026, an estimated $47.9K.
  • Neurocrine Biosciences made up 0.01% of Root Financial Partners's portfolio in Q2 2026, its #329 holding.
  • Root Financial Partners first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.